177Lu-JH04 in Patients with FAP-Positive Tumors

Recruiting now · Early Phase 1

Conditions studied: Patients with Advanced Metastatic FAP-Positive Tumors

In brief

This is a pilot study to assess the dosimetry, toxicity and response of 177Lu-JH04, a new FAP-targeted radiopharmaceutical, in patients with FAP-Positive Tumors. All patients underwent 68Ga-FAPI PET/CT for selection and were successively divided into three groups of 3 people each.The three groups received successively an approximately 3.70 GBq (100 mCi), 5.55 GBq (150 mCi) and 7.40 GBq (200 mCi) of 177Lu-JH04 up to 4 cycles.

Key facts

Study ID

NCT06636617

Run by

First Affiliated Hospital of Fujian Medical University

People needed

9

Starts

2024-08-21

Expected to finish

2025-08-31

Last updated by the study team

2024-10-10

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• progressive advanced metastatic tumors
• tumors with high FAP expression confirmed on 68Ga-FAPI PET/CT
• adequate renal, haematological, and liver function
• an Eastern Cooperative Oncology Group performance status of 0-2

You may not qualify if…

• pregnant or lactating women
• received other radionuclide therapy in the past 6 months
• received chemotherapy, radiotherapy and other anti-tumor treatments in the past 28 days

Where it is running

• Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.